ELECTROCONVULSIVE SHOCK EFFECTS ON BRAIN RECEPTORS
电休克对脑感受器的影响
基本信息
- 批准号:3380666
- 负责人:
- 金额:$ 15.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1986
- 资助国家:美国
- 起止时间:1986-07-01 至 1991-06-30
- 项目状态:已结题
- 来源:
- 关键词:alpha adrenergic receptor amphetamines antidepressants autoradiography axon beta adrenergic receptor brain mapping brain metabolism cyclic AMP electroconvulsive therapy experimental brain lesion imipramine laboratory rat mental disorder chemotherapy neurochemistry neurotransmitter receptor norepinephrine p chlorophenylalanine phenelzine phosphatidylinositols radiotracer serotonin
项目摘要
The overall objectives of this research are to compare the
effects of administration of electroconvulsive shock (ECS) and
antidepressant drugs on serotonergic and noradrenergic
receptors in rat brain. In particular, the following
hypotheses will be tested: 1) that ECS differs from most
antidepressant drug treatments in its effects on 5-HT-2
receptors, and 2) that ECS differs from most antidepressant
drug treatments in its effects on up-regulated beta-adrenergic
receptors. To test the latter hypothesis, we will use a new
model in which following highly specific lesions of 5-HT
neurons or inhibition of 5-HT synthesis, beta-adrenergic
receptors are markedly increased in brain. Among the specific
aims of this research are: 1) To determine the effects of ECS
and antidepressant drugs on the increased number of
beta-adrenergic receptors by measuring ligand binding and
isoproterenol-stimulated cyclic AMP production in brain. 2) To
use quantitative autoradiography to identify and compare the
specific brain regions in which beta-adrenergic receptors are
decreased by ECS and antidepressant drugs, and to identify the
beta receptor subtype affected by these treatments. 3) To
identify by quantitative autoradiography the specific regions
and layers of cerebral cortex in which 5-HT-2 receptors are
increased by ECS and decreased by antidepressant drugs. 4) To
compare the effects of ECS and antidepressant drugs on 5-HT-2
and alpha-1-adrenergic receptor-mediated phosphoinositide
hydrolysis. 5) To determine whether lesions of norepinephrine
axons alter the effects of ECS or antidepressant drugs on
5-HT-2 receptors.
These studies should provide new information about the effects
of ECS and antidepressant drugs on the receptor systems for the
two neurotransmitters that have been most often implicated in
depression and its treatment. This information should
contribute to an eventual understanding of the neurochemical
effects of ECS and antidepressant drugs and potentially to the
rationale for the clinical effects of electroconvulsive therapy.
本研究的总体目标是比较
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Electroconvulsive shocks increase the concentration of neocortical and hippocampal neuropeptide Y (NPY)-like immunoreactivity in the rat.
电休克会增加大鼠新皮质和海马神经肽 Y (NPY) 样免疫反应性的浓度。
- DOI:10.1016/0006-8993(90)90523-e
- 发表时间:1990
- 期刊:
- 影响因子:2.9
- 作者:Wahlestedt,C;Blendy,JA;Kellar,KJ;Heilig,M;Widerlöv,E;Ekman,R
- 通讯作者:Ekman,R
Electroconvulsive shock and reserpine increase alpha 1-adrenoceptor binding sites but not norepinephrine-stimulated phosphoinositide hydrolysis in rat brain.
电休克和利血平会增加大鼠脑中α1-肾上腺素受体的结合位点,但不会增加去甲肾上腺素刺激的磷酸肌醇水解。
- DOI:10.1016/0014-2999(88)90330-5
- 发表时间:1988
- 期刊:
- 影响因子:5
- 作者:Blendy,JA;Stockmeier,CA;Kellar,KJ
- 通讯作者:Kellar,KJ
Electroconvulsive shock increases alpha 1b- but not alpha 1a-adrenoceptor binding sites in rat cerebral cortex.
电休克会增加大鼠大脑皮层中 α1b- 肾上腺素受体的结合位点,但不会增加 α1a- 肾上腺素受体的结合位点。
- DOI:10.1111/j.1471-4159.1991.tb06350.x
- 发表时间:1991
- 期刊:
- 影响因子:4.7
- 作者:Blendy,JA;Perry,DC;Pabreza,LA;Kellar,KJ
- 通讯作者:Kellar,KJ
Electroconvulsive shock differentially increases binding to alpha-1 adrenergic receptor subtypes in discrete regions of rat brain.
电休克不同程度地增加了大鼠大脑离散区域中与 α-1 肾上腺素能受体亚型的结合。
- DOI:10.1523/jneurosci.10-08-02580.1990
- 发表时间:1990
- 期刊:
- 影响因子:0
- 作者:Blendy,JA;Grimm,LJ;Perry,DC;West-Johnsrud,L;Kellar,KJ
- 通讯作者:Kellar,KJ
Electroconvulsive shock but not antidepressant drugs increases alpha 1-adrenoceptor binding sites in rat brain.
电休克会增加大鼠大脑中的α1-肾上腺素受体结合位点,但抗抑郁药物不会增加。
- DOI:10.1016/0014-2999(87)90582-6
- 发表时间:1987
- 期刊:
- 影响因子:5
- 作者:Stockmeier,CA;McLeskey,SW;Blendy,JA;Armstrong,NR;Kellar,KJ
- 通讯作者:Kellar,KJ
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KENNETH J KELLAR其他文献
KENNETH J KELLAR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KENNETH J KELLAR', 18)}}的其他基金
Novel Ligands that Selectively Desensitize alpha4beta nAChRs for Smoking Cessatio
选择性使 α4β nAChR 脱敏以戒烟的新型配体
- 批准号:
8616367 - 财政年份:2010
- 资助金额:
$ 15.06万 - 项目类别:
Novel Ligands that Selectively Desensitize alpha4beta nAChRs for Smoking Cessatio
选择性使 α4β nAChR 脱敏以戒烟的新型配体
- 批准号:
8223233 - 财政年份:2010
- 资助金额:
$ 15.06万 - 项目类别:
Novel Ligands that Selectively Desensitize alpha4beta nAChRs for Smoking Cessatio
选择性使 α4β nAChR 脱敏以戒烟的新型配体
- 批准号:
8038405 - 财政年份:2010
- 资助金额:
$ 15.06万 - 项目类别:
Novel Ligands that Selectively Desensitize alpha4beta nAChRs for Smoking Cessatio
选择性使 α4β nAChR 脱敏以戒烟的新型配体
- 批准号:
7779037 - 财政年份:2010
- 资助金额:
$ 15.06万 - 项目类别:
Novel Ligands that Selectively Desensitize alpha4beta nAChRs for Smoking Cessatio
选择性使 α4β nAChR 脱敏以戒烟的新型配体
- 批准号:
8435485 - 财政年份:2010
- 资助金额:
$ 15.06万 - 项目类别:
NICOTINIC RECEPTORS AUTONOMIC GANGLIA AND ADRENAL GLAND
烟碱受体自主神经节和肾上腺
- 批准号:
6489471 - 财政年份:2001
- 资助金额:
$ 15.06万 - 项目类别:
Pharmacology and Regulation of Nicotinic Receptor Subtypes
烟碱受体亚型的药理学和调节
- 批准号:
8491947 - 财政年份:2001
- 资助金额:
$ 15.06万 - 项目类别:
NICOTINIC RECEPTORS AUTONOMIC GANGLIA AND ADRENAL GLAND
烟碱受体自主神经节和肾上腺
- 批准号:
6700834 - 财政年份:2001
- 资助金额:
$ 15.06万 - 项目类别:
NICOTINIC RECEPTORS AUTONOMIC GANGLIA AND ADRENAL GLAND
烟碱受体自主神经节和肾上腺
- 批准号:
6841602 - 财政年份:2001
- 资助金额:
$ 15.06万 - 项目类别:
相似海外基金
Relationship between neurotoxicity and the chemical structures of amphetamines
安非他明的神经毒性与化学结构的关系
- 批准号:
25860103 - 财政年份:2013
- 资助金额:
$ 15.06万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Search for protein expression in amphetamines treated mouse heart : Challenge to the diagnosis for the sudden death of amphetamines abusers
寻找安非他明治疗小鼠心脏中的蛋白质表达:对安非他明滥用者猝死诊断的挑战
- 批准号:
22659138 - 财政年份:2010
- 资助金额:
$ 15.06万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Novel Functionally-Selective Serotonin 5HT2 Drugs for Amphetamines Abuse/Disorder
用于治疗安非他明滥用/疾病的新型功能选择性血清素 5HT2 药物
- 批准号:
8312648 - 财政年份:2010
- 资助金额:
$ 15.06万 - 项目类别:
Novel Functionally-Selective Serotonin 5HT2 Drugs for Amphetamines Abuse/Disorder
用于治疗安非他明滥用/疾病的新型功能选择性血清素 5HT2 药物
- 批准号:
8531900 - 财政年份:2010
- 资助金额:
$ 15.06万 - 项目类别:
Novel Functionally-Selective Serotonin 5HT2 Drugs for Amphetamines Abuse/Disorder
用于治疗安非他明滥用/疾病的新型功能选择性血清素 5HT2 药物
- 批准号:
8715749 - 财政年份:2010
- 资助金额:
$ 15.06万 - 项目类别:
Novel Functionally-Selective Serotonin 5HT2 Drugs for Amphetamines Abuse/Disorder
用于治疗安非他明滥用/疾病的新型功能选择性血清素 5HT2 药物
- 批准号:
8144930 - 财政年份:2010
- 资助金额:
$ 15.06万 - 项目类别:
Translational Genetics and Dopamine Signaling in Sensitivity to Amphetamines
安非他明敏感性中的转化遗传学和多巴胺信号传导
- 批准号:
7675601 - 财政年份:2009
- 资助金额:
$ 15.06万 - 项目类别:
Simultaneous determination of ephedrines, amphetamines, cocaine, cocaine metabolites, and opiates and interaction in the rat
大鼠体内麻黄碱、安非他明、可卡因、可卡因代谢物和阿片类药物的同时测定及其相互作用
- 批准号:
17590585 - 财政年份:2005
- 资助金额:
$ 15.06万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Study for practical use of two chiral analyses of amphetamines by gas chromatography-mass spectrometry
气相色谱-质谱法对苯丙胺两种手性分析的实用化研究
- 批准号:
17590588 - 财政年份:2005
- 资助金额:
$ 15.06万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clinical Pharmacology of 3,4-Methylenedioxy Amphetamines
3,4-亚甲二氧基安非他明的临床药理学
- 批准号:
6870119 - 财政年份:2004
- 资助金额:
$ 15.06万 - 项目类别:














{{item.name}}会员




